Coronary heart disease
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1. Aged 45-75 years; 2. meet the diagnostic criteria of CHD; 3. meet the diagnostic criteria of grade I–II angina according to the Canadian Cardiovascular Society (CCS); 4. meet the diagnostic criteria of blood stasis; 5. meet the diagnostic criteria of stable angina pectoris; 6. take regular aspirin for at least one month; 7. be informed of the study and voluntarily sign an informed consent.
Exclusion criteria
Exclusion criteria: 1. mental or physical disorders; 2. pregnant, breast-feeding, and menstruating women, as well as women planning pregnancy within three months; 3. severe heart disease(acute myocardial infarction or acute myocardial infarction in six months), severe cardiopulmonary dysfunction (e.g. cardiac function II); 4. severe primary diseases, such as liver and renal hematopoietic system damage, liver function (ALT>=2 ULN, AST>=2 ULN, kidney function, Cr> 1.0 ULN), or nervous and mental disorder; 5. poorly controlled hypertension (systolic pressure >160 mmHg; or diastolic pressure>100mmHg); 6. having participated in clinical trials in the last three months; 7. underwent surgery or had hemorrhagic tendency in the last eight weeks; 8. drug allergy history or with allergic constitution; 9. diabetes; 10. poor compliance or unsuitability for this clinical trial by investigators judgment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Paraoxonase;Butyrylcholinesterase;Carboxylesterase;intestinal flora; | — |
Secondary
| Measure | Time frame |
|---|---|
| P2Y12 acceptor;PAC-1;P-selection; | — |
Countries
China
Contacts
Beijing University of Chinese Medicine, Dongzhimen hospital